Officials at GE Healthcare say the company will provide China-based Xiangxue Pharmaceutical (XPH) with a FlexFactory™ for cell therapy. The system, expected to be operational in March 2019, is a semiautomated end-to-end manufacturing platform to help scale up, digitize, and accelerate manufacturing processes for cell therapy clinical trials and future commercialization. According to GE Healthcare, this project marks the first application of FlexFactory for cell immunotherapy drugs based on high-affinity and high-specificity T-cell receptors (TCRs). XPH is focused on cancer treatments based on a new-generation TCR T-cell therapy. Cell therapy is one of the most rapidly advancing life science areas for basic cancer research and clinical applications. However, the manufacturing process is complex and is a challenge for companies to produce cell therapies at industrial scale. FlexFactory for cell therapy was developed to help companies achieve stable, safe, and scalable manufacturing of cell therapy products, notes Qing ...
Original Article: Xiangxue Pharmaceutical Purchases FlexFactory from GE Healthcare